Polytope monoclonal antibody vaccine candidates are being developed by ImmunoPrecise Antibodies (IPA) in collaboration with EVQLV for the treatment of COVID-19 infections. EVQLV, an artificial intelligence company will utilise B cell selectTM and custom DeepDisplayTM platform developed at IPA. B cell selectTM platform enables the interrogation of B-cells and generate native monoclonal antibodies from any immunised animal, independent of species. DeepDisplayTM platform is a combination of phage display platform which contains immune libraries from different animal species including transgenic animals and Ligand's OmniAb therapeutic antibody platform which develop fully human antibody with reduced immunogenicity. EVQLV will perform in-silico antibody design to discover novel antibody sequence to leverage lead candidate from IPA's discovery platform. Early research is underway in US.
In June 2020, ImmunoPrecise Antibodies (IPA) entered into collaboration with LiteVax to conduct preclinical study to determine the immunogenicity, safety and potency of IPA’s novel SARS-CoV-2 vaccine candidates, when formulated with LiteVax’s adjuvant (LVA). The study will be conducted in a swine animal model. Both parties will retain full rights to their respective proprietary assets and know-how used for the study. If the preclinical study is successful, IPA and LiteVax may then negotiate the terms for a preclinical study in a second animal model, as well as details of potential commercialisation of any resulting vaccine. Financial details were not disclosed. 
In March 2020, ImmunoPrecise Antibody and EVQLV entered into research collaboration to develop lead therapeutic and vaccine candidate against COVID-19. Under the terms of the agreement, EVQLV will perform in silico antibody design and discovery to generate novel, optimized antibody sequences leveraging lead candidate data from IPA’s discovery technologies, as well as previously published sequences. EVQLV will utilise its in-silico antibody design to generate novel antibody sequence by using IPA's B cell selectTM and custom deep displayTM technology platform to discover lead candidate against SARS-CoV-2 coronavirus infection.
Key Development Milestones
In June 2020, ImmunoPrecise Antibodies announced that they intend to conduct preclinical trial with polytope monoclonal antibody candidates in collaboration with LiteVax in August 2020. The preclinical study will determine immunogenicity, safety and potency of the candidates with an adjuvant provided by LiteVax. The study will be funded by TRANSVAC2  .
In March 2020, EVQLV submitted the first panel of candidate therapeutic antibody sequences, comprised of DNA sequences encoding for potentially therapeutic antibodies against the new coronavirus, SARS-CoV-2  .